Affiliation:
1. Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA
Abstract
Efficient and targeted delivery of a DNA payload is vital for developing safe gene therapy. Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. Adenovirus vectors can be used in gene therapy by altering the wild-type virus and making it replication-defective; specific viral genes can be removed and replaced with a segment that holds a therapeutic gene, and this vector can be used as delivery vehicle for tissue specific gene delivery. Modified conditionally replicative–oncolytic adenoviruses target tumors exclusively and have been studied in clinical trials extensively. This comprehensive review seeks to offer a summary of adenovirus vectors, exploring their characteristics, genetic enhancements, and diverse applications in clinical and preclinical settings. A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine clinical trials for various diseases. Additionally, we tackle current challenges and future avenues for optimizing adenovirus vectors, promising to open new frontiers in the fields of cell and gene therapies.
Funder
Powell Gene Therapy Center
Subject
Virology,Infectious Diseases
Reference215 articles.
1. FDA (2023). Approved Cellular and Gene Therapy Products, FDA.
2. Chavda, V.P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B.B., Kaushik, A., and Jesawadawala, M. (2023). Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 11.
3. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review);Wang;Oncol. Rep.,2021
4. A review of 65 years of human adenovirus seroprevalence;Mennechet;Expert Rev. Vaccines,2019
5. Adenoviruses in medicine: Innocuous pathogen, predator, or partner;MacNeil;Trends Mol. Med.,2023